PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Clue to unusual drug-resistant breast cancers found

2010-10-10
(Press-News.org) Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

The study is published in the Oct. 8 issue of the Journal of Biological Chemistry, where it is designated a paper of the week.

Approximately 70 percent of breast cancers express the estrogen receptor. These "ER-positive" tumors usually respond to hormone-related therapies, such as tamoxifen or aromatase inhibitors. But not always.

"We were interested in a subset of ER-positive tumors that are unusually aggressive and also drug-resistant," said Jonna Frasor, assistant professor of physiology and biophysics at the UIC College of Medicine and principal investigator of the study.

Following up on earlier observations that these aggressive ER-positive tumors express genes that respond both to estrogen and inflammatory factors called cytokines, Frasor and her colleagues focused on the gene for a drug-transporter protein which is believed to pump chemotherapy drugs out of tumor cells, making them resistant.

It is unexpected to find estrogen and inflammatory proteins seemingly working together to drive the cancer's aggressiveness, says Madhumita Pradhan, a student in Frasor's lab and first author of the paper. In many cases, estrogen is known to be protective against inflammatory processes, Pradhan said.

The researchers showed that in breast cancer cells, an inflammatory protein called NFĸB and the estrogen receptor act together to increase expression of the transporter gene. And they were able to show how.

An area on a gene called a promoter acts as an on/off switch that determines whether the gene is transcribed and the protein it encodes is produced. The promoter has spaces called response elements, where molecules can attach and help to turn the switch on or off.

"We found that the estrogen receptor gets recruited to the promoter of this gene," Frasor said. "Once there, the ER allows NFĸB to be recruited to its own response element. Once the second molecule binds, it actually stabilizes the ER and the gene is turned on to a much greater extent than with the ER alone."

This novel mechanism could have important implications in the treatment of breast cancers in which inflammation and estrogen can promote cancer progression, Frasor said.

### END


ELSE PRESS RELEASES FROM THIS DATE:

Progress toward first commercial repellent for East Coast's stinker

2010-10-10
WASHINGTON, Oct. 9, 2010 — Help may be on the way for millions of people on the East Coast bugged out about the invasion of stink bugs. Scientists have reported a key advance in efforts to develop the first commercial repellent for stinkbugs, which are emerging as a major nuisance to homeowners and a devastating pest to some farm crops. They identified a natural substance in a fungus that infects a common weed and found that it shows potential as the first stinkbug repellent. Their study appeared in ACS' bi-weekly Journal of Agricultural and Food Chemistry. Hiromitsu ...

Clinical trials demonstrate effective weight loss strategies for obese and overweight adults

2010-10-10
CHICAGO -- Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA. According to background information in the papers, obesity is among the ...

Prepared meals and incentivized weight-loss program for obese and overweight women

2010-10-10
In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 – 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010. The women were randomized into three intervention groups: in-person, center-based (167 women) or telephone based (164 women) weekly one-to-one weight loss counseling, including free-of-charge prepackaged prepared ...

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

2010-10-10
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show. Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The study included 128 patients with advanced non-small cell lung cancer who were ...

Surgical technique relieves painful spine fractures in patients with metastatic cancer

2010-10-10
A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan. Many patients with multiple myeloma, or those whose cancer has spread beyond the initial tumor site, suffer compression fractures in their spine. This is partly because the spine is one of the most common sites for metastatic spread of the disease, making the vertebrae brittle and at risk for fractures. Widely-used cancer ...

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

2010-10-10
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting. The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 ...

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

2010-10-10
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy. Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006. They found that the median overall survival grew progressively smaller for each successive chemotherapy ...

Study reveals cancer-linked epigenetic effects of smoking

2010-10-10
For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer. The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The link between smoking and cancer has been established for decades, explained Dr Yuk Ting Ma from the Cancer Research UK Institute of Cancer Studies, Birmingham, who presented the results. Smoking is the single biggest cause of cancer in the world, and years of research have confirmed that carcinogenic ...

Investigational ovarian cancer drug shows promise against platinum resistant disease

2010-10-10
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported. Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO). MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal ...

Ameripro Appliance Repair Los Angeles

2010-10-10
Ameripro Appliance Repair is the leading home, business and commercial appliance repair company in Los Angeles. Air conditioning is a wonderful thing for some people to use when the summer heat strikes. However, some people may not think about getting some of the regular maintenance carried out of the machine. Then when they go to use the machine they discover that it does not function. That is when they will want to know about the positives of Los Angeles air conditioning repair information and how it can help a person in determining the issue and knowing which service ...

LAST 30 PRESS RELEASES:

Smarter tools for policymakers: Notre Dame researchers target urban carbon emissions, building by building

Here’s how we help an iconic California fish survive the gauntlet of today’s highly modified waterways

New technique can dramatically improve laser linewidth

Forest trees and microbes choreograph their hunt for a ‘balanced diet’ under elevated CO2

Beyond health: The political effects of infectious disease outbreaks

For tastier and hardier citrus, researchers built a tool for probing plant metabolism

Stay hydrated: New sensor knows when you need a drink

Quantum internet meets space-time in this new ingenious idea

Soil erosion in mountain environments accelerated by agro-pastoral activities for 3,800 years

Optogenetic platform illuminates new antiviral strategies

A new theory explaining oscillations in tunnel magnetoresistance (TMR)

Early antibiotics alter immune function in infants

With the second grant to therapy

Research center developing digital twins for manufacturing

Colombia’s biofortified rice has untapped potential to improve nutrition. And consumers want it

Study shows pregnancy can significantly worsen risk of serious brain injury in women with arteriovenous malformations

Mapping important infrastructure could aid emergency response after hurricanes

Nighttime pistachio snacking may reshape gut microbiome in prediabetic adults

Friendship promotes neural and behavioral similarity

Neural pathway for nicotine withdrawal symptoms

How your DNA reveals your true age with astonishing accuracy

First electronic–photonic quantum chip created in commercial foundry

High-performance scientific computing can compute molecule ground-state energy

Cryo-electron microscopy – Reaction cycle of an enzyme for CO2 fixation decoded

Feeling more extroverted? Study finds you may have learned how to handle daily stress better

Kindness counts—even to a five-day-old baby

Endocrine Society guideline calls for increased screening for common cause of high blood pressure

Macromolecular gene delivery systems: advancing non-viral therapeutics with synthetic and natural polymers

Study finds political instability, environmental conditions, and social inequality accelerate aging

New insights into malaria: Proteins in the blood can reveal the severity of the disease

[Press-News.org] Clue to unusual drug-resistant breast cancers found